Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

May 27, 2026

Autobahn’s elunetirom receives FDA fast track designation to treat adjunctive bipolar

Autobahn Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for elunetirom, its lead central nervous system (CNS)-directed thyroid hormone receptor agonist.

Autobahn’s elunetirom receives FDA fast track designation to treat adjunctive bipolar